Abstract
Background: This study was conducted to determine the effect of Rheum ribes supplementation on glycemic indices and apolipoproteins in patients with type 2 diabetes mellitus (DMT2).Methods: In this randomized controlled trial, sixty type 2 diabetic patients, aged 30-60 years with body mass index (BMI) of 20-30 kg/m 2 , and hemoglobin A1c (HbA1c) of 6-8% were included. The patients were randomly assigned to receive 450 mg of Rheum ribes aqueous extract (AG), 450 mg of Rheum ribes ethanolic extract (EG) or placebo (PG), three times daily for 6 weeks. Then glucose, the homeostatic model assessment (HOMA-IR and HOMA-B) and apolipoprotein A-I (ApoA1) and apolipoprotein B (ApoB) were measured.Results: According to these findings, in the AG and EG intervention groups, we observed a significant reduction in serum levels of insulin (P=0.003 and P=0.001, respectively), HOMA-IR (P=0.01 and P=0.001, respectively) and HOMA-B (P=0.002 and P=0.001, respectively) indices, without no significant changes in glucose. There was also a significant reduction in serum levels of ApoB (P=0.006 and P=0.03, respectively) and ApoB/ApoA1 ratio (P=0.016 and P=0.04, respectively) in both AG and EG. Intervention in both AG and EG had increasing effects on ApoA1 (P=0.08 and P=0.05, respectively). None of these variables had a significant change in PG. At the end of study, there were significant differences in insulin (P=0.04), HOMA-IR (P=0.03), HOMA-B (P=0.01), ApoB (P=0.02), and ApoB/ApoA1 (P=0.03) ratio among groups.Conclusions: Rheum ribes intake may have favorable effects on insulin resistance and apolipoproteins in diabetic patients.Trial registration: The study was recorded in Iranian Registry of Clinical Trials under the registration number of IRCT201410142709N31 (Registration date: 2014-12-11, https://en.irct.ir/trial/2543 ).